Glenmark Partners With Menarini On Ryaltris

Licensing Deal For Nasal Spray Covers 33 European Countries

Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.

Europe_Night
Glenmark’s agreement with Menarini covers 33 European countries • Source: Shutterstock

Menarini Group will market Glenmark Pharmaceuticals’ Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray in 33 countries across Europe after the two firms entered into an exclusive licensing agreement.

The deal – which covers major European markets including France, Italy and Spain as well as the Balkan region –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business